Clinical Trials Logo

Clinical Trial Summary

The goal of this clinical trial is to determine if non-invasive electrical stimulation, using an electric stimulator placed on the skin of the patients back and abdomen for 30 minutes can reduce muscle spasms (spasticity) and improve walking function in patients with primary lateral sclerosis. Participants will attend one in-person clinic visit and participate in one telephone interview 24 hours after the treatment. The clinic visit will include pre-intervention, treatment and post-intervention assessments. The assessments will consist of a complete physical exam by the clinic neurologist followed by assessments and scoring of spasticity, deep tendon reflexes, gait quality, gait speed, gait endurance and balance. Patient's will rate their perceived spasticity pre, immediately post and 24 hours post treatment. The treatment involves one 30-minute electrical stimulation session, which includes application of electrode pads to the patients back and abdomen. The patient will lay supine (on their back) with a pillow placed under their knees for comfort. The pads will then be connected to an FDA approved electrical stimulator. The electrical stimulator will be turned on and current adjusted to the individual patient based on small muscle contractions in their legs. Once the current is set, the patient will lay supine for 30 minutes. After 30 minutes, the device will be turned off and electrode pads removed.


Clinical Trial Description

Objective: The primary aim of this preliminary pilot study is to assess the clinical effects of transcutaneous electrical stimulation (tES) in reducing spasticity in the lower extremities and increasing mobility in patients with Primary Lateral Sclerosis (PLS). Study population: 6 patients with a confirmed diagnosis of PLS aged 18-90 Design: Each enrolled participant will attend one in-person clinic visit and participate in one telephone interview 24 hours post-treatment. The clinic visit will include pre-intervention, treatment and post-intervention assessments. The assessments will consist of a complete physical exam by the clinic neurologist followed by assessments and scoring of spasticity, deep tendon reflexes, gait quality, gait speed, gait endurance and balance. The patients will rate their perceived spasticity pre, immediately post and 24 hours post treatment. Treatment will include a 30-minute transcutaneous electrical stimulation (tES) session where tES will be applied through two sets of electrodes positioned adjacent to the T11/T12 spinous processes and a second pair of electrodes placed para-umbilically on the lower abdomen. A current-controlled electrical stimulator will be used to deliver charge-balanced symmetrical, biphasic rectangular pulses to the paraspinal electrodes as the anode for the first phase and as the cathode for the second phase of the stimulation phase. Electrode placement will be verified by applying electrical stimulation to elicit mild posterior root-muscle (PRM) contractions in the L2-S2 innervated rectus femoris, biceps femoris, tibialis anterior, and triceps surae muscle group bilaterally with the participants relaxed in the supine position. This will be determined by palpation at the patellar and achilles tendons of both sides. While the participants remain supine, the stimulator will be set to continuous mode to deliver stimulation at a frequency of 50 Hz and pulse width of 400 microseconds, then the stimulation amplitude will be slowly increased from 0 milliamp (mA) to an amplitude that may generate minor paraesthesias (slight tingling sensations) in some individuals in the bilateral L2-S2 lower extremity dermatomes but below the level that elicited posterior motor root (PMR) contraction responses. The stimulation amplitude will be individually assessed and set for each participant, and the stimulation amplitude upper limit will be no more than 90% of the lowest PRM response for each participant. After this 30-minute tES session, the tES unit will be turned off, the electrodes removed, and the participants assessed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06012110
Study type Interventional
Source Nova Southeastern University
Contact Kayla Chomko, DPT
Phone 954-262-6387
Email kchomko@nova.edu
Status Recruiting
Phase N/A
Start date August 28, 2023
Completion date August 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03067857 - Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease Phase 1/Phase 2
Active, not recruiting NCT02567136 - Imaging Biomarkers in ALS
Recruiting NCT05204017 - Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS
Completed NCT00324454 - Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease Phase 2
Completed NCT01143428 - Oxidative Stress in Motor Neuron Disease: COSMOS Add-On Study
Completed NCT00015444 - Screening and Natural History: Primary Lateral Sclerosis and Related Disorders
Recruiting NCT06320444 - Non-invasive Spinal, Cortical, and Sensorimotor Biomarkers in Motor Neurone Disease
Not yet recruiting NCT06315673 - Digital Assessment of Speech and Fine Motor Control in ALS
Completed NCT03560661 - Acoustic and Perceptual Markers of Dysarthria in Amyotrophic Lateral Sclerosis (ALS)
Recruiting NCT04875416 - Phenotype, Genotype and Biomarkers 2
Active, not recruiting NCT03912987 - TRIAL READY (Clinical Trial Readiness)
Withdrawn NCT05830214 - Digital Smartwatch Measurements as Potential Biomarkers for Remote Disease Tracking in ALS
Recruiting NCT03489278 - Clinical Procedures to Support Research in ALS
Completed NCT02852278 - A Patient Centric Motor Neuron Disease Activities of Daily Living Scale
Completed NCT02574390 - Answer ALS: Individualized Initiative for ALS Discovery
Completed NCT00023075 - Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis N/A
Enrolling by invitation NCT02327845 - Phenotype, Genotype & Biomarkers in ALS and Related Disorders
Completed NCT00677768 - Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS) N/A